Meeting
2018 ASCO Annual Meeting
Results of a randomized phase III study of nimotuzumab in combination with concurrent radiotherapy and cisplatin versus radiotherapy and cisplatin alone, in locally advanced squamous cell carcinoma of the head and neck.
Presenter
Vijay Maruti Patil, MD, MBBS
Tata Memorial Centre
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Videos & Slides Details
Session Type
Oral Abstract Session
Session Title
Head and Neck Cancer
Track
Head and Neck Cancer
Sub Track
Local-Regional Disease
Clinical Trial Registration Number
CTRI/2014/09/004980
Citation
J Clin Oncol 36, 2018 (suppl; abstr 6000)
DOI
10.1200/JCO.2018.36.15_suppl.6000
Abstract #
6000
Abstract Disclosures
Similar Videos & Slides
Videos & Slides
2024 ASCO Annual Meeting
Long term results of a randomized phase III study of nimotuzumab in combination with concurrent radiotherapy and cisplatin versus radiotherapy and cisplatin alone, in locally advanced squamous cell carcinoma of the head and neck.
Speaker: Vijay Maruti Patil, MD, MBBS
Videos & Slides
2022 ASCO Annual Meeting
An open-label, noninferiority phase III RCT of weekly versus three weekly cisplatin and radical radiotherapy in locally advanced head and neck squamous cell carcinoma (ConCERT trial).
Speaker: Atul Sharma, MD
Videos & Slides
2016 ASCO Annual Meeting
Radiation plus concurrent nimotuzumab versus CDDP in locally advanced nasopharyngeal cancer: Results of a phase III randomised trial.
Speaker: Lin Kong
Speaker: Mehmet Asim Bilen, MD